Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (9): 850-854.DOI: 10.3969/j.issn.1673-8640.2022.09.011
Previous Articles Next Articles
Received:2021-09-13
Revised:2022-01-03
Online:2022-09-30
Published:2022-10-25
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.09.011
| 变量 | 赋值 | 变量 | 赋值 |
|---|---|---|---|
| 性别（X1） | 男=0、女=1 | NLR（X5） | 实测值 |
| 年龄（X2） | 实测值 | PLR（X6） | 实测值 |
| FEV1（X3） | 实测值 | MPV（X7） | 实测值 |
| CAT评分（X4） | 实测值 | 预后情况（Y1） | 预后良好=0、预后不良=1 |
| 变量 | 赋值 | 变量 | 赋值 |
|---|---|---|---|
| 性别（X1） | 男=0、女=1 | NLR（X5） | 实测值 |
| 年龄（X2） | 实测值 | PLR（X6） | 实测值 |
| FEV1（X3） | 实测值 | MPV（X7） | 实测值 |
| CAT评分（X4） | 实测值 | 预后情况（Y1） | 预后良好=0、预后不良=1 |
| 组别 | 例数 | NLR/% | PLR/% | MPV/fL |
|---|---|---|---|---|
| AECOPD组 | 189 | 4.14（3.52,4.93） | 127.04（115.83,139.98） | 10.55（10.07,11.35） |
| 正常对照组 | 165 | 3.57（3.02,4.42） | 120.55（113.49,132.21） | 8.29（7.53,10.75） |
| U值 | 48.751 | 37.202 | 5.871 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | NLR/% | PLR/% | MPV/fL |
|---|---|---|---|---|
| AECOPD组 | 189 | 4.14（3.52,4.93） | 127.04（115.83,139.98） | 10.55（10.07,11.35） |
| 正常对照组 | 165 | 3.57（3.02,4.42） | 120.55（113.49,132.21） | 8.29（7.53,10.75） |
| U值 | 48.751 | 37.202 | 5.871 | |
| P值 | <0.001 | <0.001 | <0.001 |
| 组别 | 例数 | 性别 | 年龄/岁 | FEV1/L | |
|---|---|---|---|---|---|
| 男/[例（%）] | 女/[例（%）] | ||||
| 预后不良组 | 25 | 14（56.00） | 11（44.00） | 61.21±10.39 | 1.15±0.20 |
| 预后良好组 | 164 | 87（53.05） | 77（46.95） | 65.62±12.29 | 1.60±0.28 |
| 统计值 | 0.076 | 1.703 | 7.732 | ||
| P值 | 0.783 | 0.090 | <0.001 | ||
| 组别 | CAT评分/分 | NLR/% | PLR/% | MPV/fL | |
| 预后不良组 | 23.68±4.28 | 8.10（6.65,9.03） | 157.93（109.75,175.75） | 11.94（9.93,12.91） | |
| 预后良好组 | 13.25±2.50 | 4.05（3.48,4.65） | 126.38（115.94,135.12） | 10.47（10.08,11.17） | |
| 统计值 | 17.395 | 22.251 | 13.021 | 3.399 | |
| P值 | <0.001 | <0.001 | <0.001 | 0.001 | |
| 组别 | 例数 | 性别 | 年龄/岁 | FEV1/L | |
|---|---|---|---|---|---|
| 男/[例（%）] | 女/[例（%）] | ||||
| 预后不良组 | 25 | 14（56.00） | 11（44.00） | 61.21±10.39 | 1.15±0.20 |
| 预后良好组 | 164 | 87（53.05） | 77（46.95） | 65.62±12.29 | 1.60±0.28 |
| 统计值 | 0.076 | 1.703 | 7.732 | ||
| P值 | 0.783 | 0.090 | <0.001 | ||
| 组别 | CAT评分/分 | NLR/% | PLR/% | MPV/fL | |
| 预后不良组 | 23.68±4.28 | 8.10（6.65,9.03） | 157.93（109.75,175.75） | 11.94（9.93,12.91） | |
| 预后良好组 | 13.25±2.50 | 4.05（3.48,4.65） | 126.38（115.94,135.12） | 10.47（10.08,11.17） | |
| 统计值 | 17.395 | 22.251 | 13.021 | 3.399 | |
| P值 | <0.001 | <0.001 | <0.001 | 0.001 | |
| 因素 | β值 | 标准误 | Wald值 | P值 | 比值比值（95%可信区间） |
|---|---|---|---|---|---|
| FEV1 | -1.678 | 0.631 | 7.071 | 0.003 | 0.187（0.113~0.725） |
| CAT评分 | 1.878 | 0.553 | 11.533 | <0.001 | 6.540（6.032~7.238） |
| NLR | 1.996 | 0.532 | 14.077 | <0.001 | 7.360（6.703~8.788） |
| PLR | 1.812 | 0.575 | 9.931 | 0.001 | 6.123（5.362~6.947） |
| MPV | 1.755 | 0.622 | 7.961 | 0.003 | 5.783（5.121~6.378） |
| 因素 | β值 | 标准误 | Wald值 | P值 | 比值比值（95%可信区间） |
|---|---|---|---|---|---|
| FEV1 | -1.678 | 0.631 | 7.071 | 0.003 | 0.187（0.113~0.725） |
| CAT评分 | 1.878 | 0.553 | 11.533 | <0.001 | 6.540（6.032~7.238） |
| NLR | 1.996 | 0.532 | 14.077 | <0.001 | 7.360（6.703~8.788） |
| PLR | 1.812 | 0.575 | 9.931 | 0.001 | 6.123（5.362~6.947） |
| MPV | 1.755 | 0.622 | 7.961 | 0.003 | 5.783（5.121~6.378） |
| 项目 | AUC （95%可信区间） | 最佳 临界值 | 敏感性/ % | 特异性/ % |
|---|---|---|---|---|
| NLR | 0.767（0.700~0.825） | 5.72% | 76.00 | 91.46 |
| PLR | 0.735（0.666~0.797） | 148.31% | 68.00 | 96.34 |
| MPV | 0.738（0.669~0.799） | 11.69 fL | 72.00 | 94.51 |
| 联合 | 0.960（0.922~0.983） | 96.00 | 90.85 |
| 项目 | AUC （95%可信区间） | 最佳 临界值 | 敏感性/ % | 特异性/ % |
|---|---|---|---|---|
| NLR | 0.767（0.700~0.825） | 5.72% | 76.00 | 91.46 |
| PLR | 0.735（0.666~0.797） | 148.31% | 68.00 | 96.34 |
| MPV | 0.738（0.669~0.799） | 11.69 fL | 72.00 | 94.51 |
| 联合 | 0.960（0.922~0.983） | 96.00 | 90.85 |
| [1] |
ZHONG N, WANG C, YAO W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey[J]. Am J Respir Crit Care Med, 2007, 176(8):753-760.
DOI URL |
| [2] | 林泽辉, 许银姬. 慢性阻塞性肺疾病急性加重患者住院死亡结局预测模型研究[J]. 临床肺科杂志, 2020, 25(8):1175-1179. |
| [3] |
SIVAPALAN P, INGEBRIGTSEN T S, RASMUSSEN D B, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia:nationwide data on 67 000 patients with COPD followed for 12 months[J]. BMJ Open Respir Res, 2019, 6(1):e000407.
DOI URL |
| [4] | GUTTA L, M S, AHMED T. NLR and PLR ratios-accessible and affordable predictors of disease severity in COPD[J]. J Assoc Physicians India, 2022, 70(4):11-12. |
| [5] | 喻瑞, 黎友伦. NLR、PLR及RCI对慢性阻塞性肺疾病严重程度的预测价值[J]. 重庆医学, 2022, 51(11):1902-1907. |
| [6] |
AHIN F, KOAR A F, ASLAN A F, et al. Serum biomarkers in patients with stable and acute exacerbation of chronic obstructive pulmonary disease: a comparative study[J]. J Med Biochem, 2019, 38(4):503-511.
DOI PMID |
| [7] | 卓超洲, 沈观乐, 余瑞林, 等. NLR, PLR在慢性阻塞性肺疾病合并肺间质纤维化中的临床应用价值[J]. 临床肺科杂志, 2019, 24(12):2161-2165. |
| [8] | 曹亮, 赵建清, 钱海红, 等. 静脉血平均血小板体积对慢性阻塞性肺疾病急性加重恢复期患者的诊断价值[J]. 山东医药, 2018, 58(17):72-74. |
| [9] | 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4):255-264. |
| [10] |
KOULENTI D, PARISELLA F R, XU E, et al. The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(4):637-647.
DOI URL |
| [11] |
KICHLOO A, ALJADAH M, VIPPARLA N, et al. Optimal glucocorticoid dose and the effects on mortality, length of stay,and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)[J]. J Investig Med, 2019, 67(8):1161-1164.
DOI URL |
| [12] |
ZHANG H, LI J, YU X, et al. Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1):735.
DOI PMID |
| [13] | 郭淑轶, 张建国. NT-proBNP与慢阻肺急性加重期患者预后的相关性研究[J]. 临床医学工程, 2021, 28(4):443-444. |
| [14] | 杨凤. 降钙素原、C反应蛋白联合检测在慢性阻塞性肺疾病急性加重期中的临床意义[J]. 中国全科医学, 2020, 23(S1):173-174. |
| [15] | 胡斯明, 徐晓, 徐国鹏, 等. PLR和NLR在慢性阻塞性肺疾病急性加重病情评估中的临床价值[J]. 中国实用医药, 2019, 14(33):7-10. |
| [16] | 张果果. 探讨PLR、NLP及C反应蛋白水平检测在慢阻肺急性加重诊断中的应用[J]. 数理医药学杂志, 2020, 33(11):1608-1610. |
| [17] |
EMAMI ARDESTANI M, ALAVI-NAEINI N. Evaluation of the relationship of neutrophil-to lymphocyte ratio and platelet-to-lymphocyte ratio with in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Clin Respir J, 2021, 15(4):382-388.
DOI PMID |
| [18] |
KARADENIZ G, AKTOĞU S, ERER O F, et al. Predictive value of platelet-to-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease[J]. Biomark Med, 2016, 10(7):701-710.
DOI PMID |
| [19] | 黄燕, 党傲, 张家春. 慢性阻塞性肺疾病患者血清中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、降钙素原水平与急性加重风险的相关性研究[J]. 实用医院临床杂志, 2022, 19(1):161-164. |
| [20] | HLAPI I, SOMBORAC-BAURA A, POPOVI- GRLE S, et al. Platelet indices in stable chronic obstructive pulmonary disease-association with inflammatory markers,comorbidities and therapy[J]. Biochem Med (Zagreb), 2020, 30(1):010701. |
| [21] |
LIU J, LIU J, ZOU Y. Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation[J]. Biosci Rep, 2019, 39(5):BSR20190675.
DOI URL |
| [22] |
EL-GAZZAR A G, KAMEL M H, ELBAHNASY O K M, et al. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients[J]. Expert Rev Respir Med, 2020, 14(1):111-116.
DOI URL |
| [23] |
ARCHONTOGEORGIS K, VOULGARIS A, PAPANAS N, et al. Mean platelet volume and platelet distribution width in patients with obstructive sleep apnea syndrome and concurrent chronic obstructive pulmonary disease[J]. Clin Appl Thromb Hemost, 2018, 24(8):1216-1222.
DOI URL |
| [24] | 张辉, 伍冬冬, 马东波, 等. 血小板平均体积与血小板计数比值预测老年人慢性阻塞性肺疾病急性加重期近期预后的临床价值[J]. 中华老年医学杂志, 2020, 39(6):627-631. |
| [25] | 包蕾, 王永, 刘亚玲, 等. 第一秒用力呼气容积联合BODE评分对慢性阻塞性肺疾病合并肺结核患者预后的预测价值[J]. 内科急危重症杂志, 2019, 25(1):41-44. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
